巴西痛风药物治疗的关键综述

Q Medicine

Revista Brasileira De Reumatologia Pub Date : 2017-07-01 DOI:10.1016/j.rbr.2016.06.009

Valderilio Feijó Azevedo , Maicon Piana Lopes , Nathan Marostica Catholino , Eduardo dos Santos Paiva , Vitor Andrei Araújo , Geraldo da Rocha Castelar Pinheiro

{"title":"巴西痛风药物治疗的关键综述","authors":"Valderilio Feijó Azevedo , Maicon Piana Lopes , Nathan Marostica Catholino , Eduardo dos Santos Paiva , Vitor Andrei Araújo , Geraldo da Rocha Castelar Pinheiro","doi":"10.1016/j.rbr.2016.06.009","DOIUrl":null,"url":null,"abstract":"<div><p>Gout is considered the most common form of inflammatory arthritis in men over 40 years. The authors present a brief review of the current treatment of gout and discuss the existing pharmacological limitations in Brazil for the treatment of this disease. Although allopurinol is still the main drug administered for decreasing serum levels of uric acid in gout patients in this country, the authors also present data that show a great opportunity for the Brazilian drug market for the treatment of hyperuricemia and gout and especially for patients using private and public (SUS) health care systems.</p></div>","PeriodicalId":48991,"journal":{"name":"Revista Brasileira De Reumatologia","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2017-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.rbr.2016.06.009","citationCount":"9","resultStr":"{\"title\":\"Revisão crítica do tratamento medicamentoso da gota no Brasil\",\"authors\":\"Valderilio Feijó Azevedo , Maicon Piana Lopes , Nathan Marostica Catholino , Eduardo dos Santos Paiva , Vitor Andrei Araújo , Geraldo da Rocha Castelar Pinheiro\",\"doi\":\"10.1016/j.rbr.2016.06.009\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Gout is considered the most common form of inflammatory arthritis in men over 40 years. The authors present a brief review of the current treatment of gout and discuss the existing pharmacological limitations in Brazil for the treatment of this disease. Although allopurinol is still the main drug administered for decreasing serum levels of uric acid in gout patients in this country, the authors also present data that show a great opportunity for the Brazilian drug market for the treatment of hyperuricemia and gout and especially for patients using private and public (SUS) health care systems.</p></div>\",\"PeriodicalId\":48991,\"journal\":{\"name\":\"Revista Brasileira De Reumatologia\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2017-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.rbr.2016.06.009\",\"citationCount\":\"9\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revista Brasileira De Reumatologia\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0482500417300712\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Brasileira De Reumatologia","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0482500417300712","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 9

摘要

痛风被认为是40岁以上男性最常见的炎症性关节炎。作者简要回顾了目前痛风的治疗，并讨论了巴西治疗这种疾病的现有药理学局限性。尽管别嘌呤醇仍然是该国降低痛风患者血清尿酸水平的主要药物，但作者也提供了数据，表明巴西药物市场在治疗高尿酸血症和痛风方面有很大的机会，特别是对于使用私人和公共(SUS)卫生保健系统的患者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Revisão crítica do tratamento medicamentoso da gota no Brasil

Gout is considered the most common form of inflammatory arthritis in men over 40 years. The authors present a brief review of the current treatment of gout and discuss the existing pharmacological limitations in Brazil for the treatment of this disease. Although allopurinol is still the main drug administered for decreasing serum levels of uric acid in gout patients in this country, the authors also present data that show a great opportunity for the Brazilian drug market for the treatment of hyperuricemia and gout and especially for patients using private and public (SUS) health care systems.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Revista Brasileira De Reumatologia RHEUMATOLOGY-

CiteScore

0.82

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： RBR nasceu da necessidade de se criar um órgão oficial da SBR que pudesse divulgar a produção científica dos reumatologistas brasileiros. O primeiro número foi publicado em setembro de 1957. A partir do volume 18 (1978), passou a seis números, com periodicidade atual. A RBR, em sua trajetória, tem sido objeto de constantes mudanças, sempre visando ao seu aprimoramento e revitalização, tanto em sua apresentação como em seu conteúdo.